AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$INBX

Kayyem Jon Faiz purchased $500K of INBX (indirect holdings)

Kayyem Jon Faiz purchased 5,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at $100.00 ($0.50M total) on 2026-09-16.

Original reporting
SEC EDGAR · Kayyem Jon Faiz
Published Sep 17, 2026, 9:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Bullish
medium confidence
Mentioned
$INBX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXBullishLow
01

Why it matters

The purchase adds to the director's stake, potentially indicating confidence in upcoming developments.

02

Market read

Small insider buy; modest relevance for traders monitoring biotech insider activity.

03

What to watch

No disclosed 10b5-1 plan; purchase may be opportunistic rather than strategic.

Relevance 6/10Novelty 6/10Timing: filed 2026-09-17

Background

Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

Director Kayyem Jon Faiz bought 5,000 shares at $100 each, $500K total, increasing holdings to 429,360 shares.

Expected impact

Potential slight upward pressure if market perceives confidence.

Evidence & confidence

Director-level insider buying $500K is a positive signal but size is modest relative to market cap.

Market effects

Sector

Biotech sector may see minor positive sentiment from insider buying.

Regional

US biotech market unaffected broadly.

Global

Limited to investors tracking INBX.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong bullish sign.

Key entities

  • Company
    Inhibrx Biosciences, Inc.

    Biotech firm developing therapies.

  • Insider
    Kayyem Jon Faiz

    Director of INBX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min